Assay Detail
Binding
CHEMBL4707266
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Inhibition of PI3K/AKT/mTOR signaling in human HepG2 cells assessed as reduction in EGF-stimulated phosphorylation of Akt at S473 residue incubated for 3 hrs followed by stimulation with 50 ng/ml growth factor EGF for 15 mins by by ELISA
4
Total Activities
4
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Binding |
| Organism | Homo sapiens |
| Cell Type | HepG2 |
| Confidence | 0 — Uncurated / Unknown |
| Curated By | Autocuration |
Publication
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| EC50 | 4 | 6.63 | 6.89 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL4744689 | — | — | 1 | 6.89 |
| CHEMBL521851 | PICTILISIB | 2.0 | 1 | 6.77 |
| CHEMBL4749655 | — | — | 1 | 6.24 |
| CHEMBL98 | VORINOSTAT | 4.0 | 1 | - |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL4744689 | — | EC50 | = | 130.0 | nM | 6.89 |
| CHEMBL521851 | PICTILISIB | EC50 | = | 170.0 | nM | 6.77 |
| CHEMBL4749655 | — | EC50 | = | 580.0 | nM | 6.24 |
| CHEMBL98 | VORINOSTAT | EC50 | > | 30000.0 | nM | - |